The DOD Lung Cancer Research Program offers the Collaborative Translational Research Award (CTRA) to foster multi-institutional, multi-disciplinary partnerships between clinicians and laboratory scientists. This grant aims to accelerate the translation of promising lung cancer research into clinical applications. Projects must address at least two of seven key areas, including enhancing early detection, improving screening tools, understanding molecular mechanisms, developing innovative prevention and treatment strategies, and identifying markers for treatment response or resistance. The CTRA funds collaborations involving four independent investigators—an Initiating PI and three Partnering PIs—from a minimum of two distinct institutions. At least one partner must be a clinician, and two must have lung cancer research or patient care experience, ensuring equal intellectual contribution from all team members.
Opportunity ID: 48868
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | W81XWH-09-LCRP-CTRA |
| Funding Opportunity Title: | FY09 DOD Lung Cancer Research Program Collaborative Translational Research Award |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement Grant |
| Category of Funding Activity: | Science and Technology and other Research and Development |
| Category Explanation: | – |
| Expected Number of Awards: | 2 |
| Assistance Listings: | 12.420 — Military Medical Research and Development |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 3 |
| Posted Date: | Aug 03, 2009 |
| Last Updated Date: | Aug 28, 2009 |
| Original Closing Date for Applications: | Dec 03, 2009 |
| Current Closing Date for Applications: | Dec 03, 2009 |
| Archive Date: | Jan 02, 2010 |
| Estimated Total Program Funding: | $10,500,000 |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility” |
| Additional Information on Eligibility: | – |
Additional Information
| Agency Name: | Dept. of the Army — USAMRAA |
| Description: | The LCRP Collaborative Translational Research Award (CTRA) supports partnerships between clinicians and laboratory scientists at multiple institutions to conduct translational research in lung cancer.The purpose of the CTRA is to support multi-institutional, multi-disciplinary collaborations among clinicians and laboratory scientists that will accelerate the movement of promising ideas in lung cancer into clinical applications.The FY09 LCRP CTRA ONLY accepts applications that address at least two of the seven Areas of Emphasis listed below. Identification or development of non-invasive or minimally invasive tools to improve the detection of the initial stages of lung cancer Identification and development of tools for screening or early detection of lung cancer. Screening may include, but is not limited to, computed tomography scans, X-rays, other imaging, biomarkers, genetics/genomics/proteomics, and assessment of risk factors Understanding the molecular mechanisms that lead to clinically significant lung cancer Identification of the mechanisms that lead to the development of the various types of lung cancer Identification of innovative strategies for prevention and treatment of early lung cancer Understanding predictive and prognostic markers to identify responders and non-responders Understanding acquired resistance to treatmentThe CTRA supports the development of translational research collaborations among four independent investigators (known as partners). The four partners, consisting of an Initiating Principal Investigator (PI) and three Partnering PIs, must be from at least two distinct institutions. The proposed research must address two or more of the seven Areas of Emphasis in a manner that would maximize the collective expertise of the investigators involved. At least one partner must be a clinician, and at least two partners must have experience either in lung cancer research or lung cancer patient care. It should be clear that all partners have equal intellectual input into the design of the research project. A proposed project in which one of the partners merely supplies tissue samples or access to patients will not meet the intent of this mechanism. See the Program Announcement for the full Funding Opportunity Description. |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
PA HELP: 301-619-7079; cdmrp.pa@amedd.army.mil
eReceipt HELP: 301-682-5507; help@cdmrp.org Email:cdmrp.pa@amedd.army.mil |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
| The purpose of this modification is to revise: (1) the Program Announcement document, (2) the Application Instructions & General Information document, and (3) the Application Form Package. The revised Application Form Package included in this modification must be used in completing the application. Failure to use this Application Form Package may result in the rejection of the application when submitted in Grants.gov. | Aug 28, 2009 | |
| The purpose of this modification is to revise: (1) the Program Announcement document, (2) the Application Instructions & General Information document, and (3) the Application Form Package. The revised Application Form Package included in this modification must be used in completing the application. Failure to use this Application Form Package may result in the rejection of the application when submitted in Grants.gov. | Aug 28, 2009 | |
| Aug 28, 2009 |
DISPLAYING: Synopsis 3
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | W81XWH-09-LCRP-CTRA |
| Funding Opportunity Title: | FY09 DOD Lung Cancer Research Program Collaborative Translational Research Award |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement Grant |
| Category of Funding Activity: | Science and Technology and other Research and Development |
| Category Explanation: | – |
| Expected Number of Awards: | 2 |
| Assistance Listings: | 12.420 — Military Medical Research and Development |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 3 |
| Posted Date: | Aug 03, 2009 |
| Last Updated Date: | Aug 28, 2009 |
| Original Closing Date for Applications: | Dec 03, 2009 |
| Current Closing Date for Applications: | Dec 03, 2009 |
| Archive Date: | Jan 02, 2010 |
| Estimated Total Program Funding: | $10,500,000 |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility” |
| Additional Information on Eligibility: | – |
Additional Information
| Agency Name: | Dept. of the Army — USAMRAA |
| Description: | The LCRP Collaborative Translational Research Award (CTRA) supports partnerships between clinicians and laboratory scientists at multiple institutions to conduct translational research in lung cancer.The purpose of the CTRA is to support multi-institutional, multi-disciplinary collaborations among clinicians and laboratory scientists that will accelerate the movement of promising ideas in lung cancer into clinical applications.The FY09 LCRP CTRA ONLY accepts applications that address at least two of the seven Areas of Emphasis listed below. Identification or development of non-invasive or minimally invasive tools to improve the detection of the initial stages of lung cancer Identification and development of tools for screening or early detection of lung cancer. Screening may include, but is not limited to, computed tomography scans, X-rays, other imaging, biomarkers, genetics/genomics/proteomics, and assessment of risk factors Understanding the molecular mechanisms that lead to clinically significant lung cancer Identification of the mechanisms that lead to the development of the various types of lung cancer Identification of innovative strategies for prevention and treatment of early lung cancer Understanding predictive and prognostic markers to identify responders and non-responders Understanding acquired resistance to treatmentThe CTRA supports the development of translational research collaborations among four independent investigators (known as partners). The four partners, consisting of an Initiating Principal Investigator (PI) and three Partnering PIs, must be from at least two distinct institutions. The proposed research must address two or more of the seven Areas of Emphasis in a manner that would maximize the collective expertise of the investigators involved. At least one partner must be a clinician, and at least two partners must have experience either in lung cancer research or lung cancer patient care. It should be clear that all partners have equal intellectual input into the design of the research project. A proposed project in which one of the partners merely supplies tissue samples or access to patients will not meet the intent of this mechanism. See the Program Announcement for the full Funding Opportunity Description. |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
PA HELP: 301-619-7079; cdmrp.pa@amedd.army.mil
eReceipt HELP: 301-682-5507; help@cdmrp.org Email:cdmrp.pa@amedd.army.mil |
DISPLAYING: Synopsis 2
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | W81XWH-09-LCRP-CTRA |
| Funding Opportunity Title: | FY09 DOD Lung Cancer Research Program Collaborative Translational Research Award |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement Grant |
| Category of Funding Activity: | Science and Technology and other Research and Development |
| Category Explanation: | – |
| Expected Number of Awards: | 2 |
| Assistance Listings: | 12.420 — Military Medical Research and Development |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 2 |
| Posted Date: | Aug 28, 2009 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | – |
| Current Closing Date for Applications: | Dec 03, 2009 |
| Archive Date: | Jan 02, 2010 |
| Estimated Total Program Funding: | $10,500,000 |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility” |
| Additional Information on Eligibility: | – |
Additional Information
| Agency Name: | Dept. of the Army — USAMRAA |
| Description: | The LCRP Collaborative Translational Research Award (CTRA) supports partnerships between clinicians and laboratory scientists at multiple institutions to conduct translational research in lung cancer.The purpose of the CTRA is to support multi-institutional, multi-disciplinary collaborations among clinicians and laboratory scientists that will accelerate the movement of promising ideas in lung cancer into clinical applications.The FY09 LCRP CTRA ONLY accepts applications that address at least two of the seven Areas of Emphasis listed below. Identification or development of non-invasive or minimally invasive tools to improve the detection of the initial stages of lung cancer Identification and development of tools for screening or early detection of lung cancer. Screening may include, but is not limited to, computed tomography scans, X-rays, other imaging, biomarkers, genetics/genomics/proteomics, and assessment of risk factors Understanding the molecular mechanisms that lead to clinically significant lung cancer Identification of the mechanisms that lead to the development of the various types of lung cancer Identification of innovative strategies for prevention and treatment of early lung cancer Understanding predictive and prognostic markers to identify responders and non-responders Understanding acquired resistance to treatmentThe CTRA supports the development of translational research collaborations among four independent investigators (known as partners). The four partners, consisting of an Initiating Principal Investigator (PI) and three Partnering PIs, must be from at least two distinct institutions. The proposed research must address two or more of the seven Areas of Emphasis in a manner that would maximize the collective expertise of the investigators involved. At least one partner must be a clinician, and at least two partners must have experience either in lung cancer research or lung cancer patient care. It should be clear that all partners have equal intellectual input into the design of the research project. A proposed project in which one of the partners merely supplies tissue samples or access to patients will not meet the intent of this mechanism. See the Program Announcement for the full Funding Opportunity Description. |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
PA HELP: 301-619-7079; cdmrp.pa@amedd.army.mil
eReceipt HELP: 301-682-5507; help@cdmrp.org Email:cdmrp.pa@amedd.army.mil |
DISPLAYING: Synopsis 1
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | W81XWH-09-LCRP-CTRA |
| Funding Opportunity Title: | FY09 DOD Lung Cancer Research Program Collaborative Translational Research Award |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement Grant |
| Category of Funding Activity: | Science and Technology and other Research and Development |
| Category Explanation: | – |
| Expected Number of Awards: | 2 |
| Assistance Listings: | 12.420 — Military Medical Research and Development |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Aug 28, 2009 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | – |
| Current Closing Date for Applications: | Dec 03, 2009 |
| Archive Date: | Jan 02, 2010 |
| Estimated Total Program Funding: | $10,500,000 |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility” |
| Additional Information on Eligibility: | – |
Additional Information
| Agency Name: | Dept. of the Army — USAMRAA |
| Description: | The LCRP Collaborative Translational Research Award (CTRA) supports partnerships between clinicians and laboratory scientists at multiple institutions to conduct translational research in lung cancer. The purpose of the CTRA is to support multi-institutional, multi-disciplinary collaborations among clinicians and laboratory scientists that will accelerate the movement of promising ideas in lung cancer into clinical applications. The FY09 LCRP CTRA ONLY accepts applications that address at least two of the seven Areas of Emphasis listed below. Identification or development of non-invasive or minimally invasive tools to improve the detection of the initial stages of lung cancer Identification and development of tools for screening or early detection of lung cancer. Screening may include, but is not limited to, computed tomography scans, X-rays, other imaging, biomarkers, genetics/genomics/proteomics, and assessment of risk factors Understanding the molecular mechanisms that lead to clinically significant lung cancer Identification of the mechanisms that lead to the development of the various types of lung cancer Identification of innovative strategies for prevention and treatment of early lung cancer Understanding predictive and prognostic markers to identify responders and non-responders Understanding acquired resistance to treatment The CTRA supports the development of translational research collaborations among four independent investigators (known as partners). The four partners, consisting of an Initiating Principal Investigator (PI) and three Partnering PIs, must be from at least two distinct institutions. The proposed research must address two or more of the seven Areas of Emphasis in a manner that would maximize the collective expertise of the investigators involved. At least one partner must be a clinician, and at least two partners must have experience either in lung cancer research or lung cancer patient care. It should be clear that all partners have equal intellectual input into the design of the research project. A proposed project in which one of the partners merely supplies tissue samples or access to patients will not meet the intent of this mechanism. See the Program Announcement for the full Funding Opportunity Description. |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
PA HELP: 301-619-7079; cdmrp.pa@amedd.army.mil
eReceipt HELP: 301-682-5507; help@cdmrp.org Email:cdmrp.pa@amedd.army.mil |
Related Documents
Folder 48868 Full Announcement-1 -> fy09 dod lcrp ctra pa edited_post saab-7-30-09 final.pdf
Folder 48868 Full Announcement-1 -> biosketchjune09.pdf
Folder 48868 Full Announcement-1 -> budget form reader.pdf
Packages
| Agency Contact Information: | PA HELP: 301-619-7079; cdmrp.pa@amedd.army.mil eReceipt HELP: 301-682-5507; help@cdmrp.org Email: cdmrp.pa@amedd.army.mil |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| 12.420 | PKG00013417 | Aug 03, 2009 | Dec 03, 2009 | View |
Package 1
Mandatory forms
48868 RR_SF424-1.1.pdf
48868 RR_PerformanceSite-1.1.pdf
Optional forms
48868 RR_KeyPersonExpanded-1.1.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
